Ent This study was supported by the Portuguese Foundation for Science and Technology, via a PhD Grant (SFRH/BD/65483/2009) and Strategic Project (PEst-C/SAU/UI3282/2011), and by COMPETE. Author facts 1 Laboratory of Pharmacology Experimental Therapeutics, IBILI, Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, Celas, Coimbra 3000-548, Portugal. 2Internal Medicine Division, Common Hospital, University and Hospital Centre of Coimbra, Quinta dos Vales, S. Martinho do Bispo, Coimbra 3041-801, Portugal. 3Neurology Department, Basic Hospital, University and Hospital Centre of Coimbra, Quinta dos Vales, S. Martinho do Bispo, Coimbra 3041-801, Portugal. 4Pharmacology and Pharmacotoxicology Unit, Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, Lisbon 1649-003, Portugal. 5ESAV, Polytechnic Institute of Viseu, Av. Cor. Jos?Maria Vale de Andrade, Campus Polit nico, Viseu 3504-510, Portugal.Mascarenhas-Melo et al. Cardiovascular Diabetology 2013, 12:61 http://cardiab/content/12/1/Page 13 ofReceived: five February 2013 Accepted: 30 March 2013 Published: 9 April 2013 References 1. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE: Danger of cardiovascular and all-cause mortality in people with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Life-style Study (AusDiab). Circulation 2007, 116(two):151?57. two. Cortez-Dias N, Martins S, Belo A, Fiuza M: VALSIM. Prevalence, management and manage of diabetes mellitus and linked danger elements in principal wellness care in Portugal. Rev Port Cardiol 2010, 29(four):509?37. three. Gardete-Correia L, Boavida JM, Raposo JF, Mesquita AC, Fona C, Carvalho R, Massano-Cardoso S: 1st diabetes prevalence study in Portugal: PREVADIAB study. Diabet Med 2010, 27(eight):879?81.Formula of Fmoc-Pra-OH 4. Wild S, Roglic G, Green A, Sicree R, King H: International prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047?053. 5. Fox CS: Cardiovascular illness threat variables, kind two diabetes mellitus, along with the Framingham Heart Study. Trends Cardiovasc Med 2010, 20(3):90?5. six. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J: Emerging risk elements collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular illness: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215?222. 7. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular illness mortality in middle-aged males.Formula of Silver acetate JAMA 2002, 288(21):2709?716.PMID:23460641 eight. Leuzzi C, Marzullo R, Modena MG: Is menopause a threat aspect for ischemic heart disease in females? G Ital Cardiol 2012, 13:401?06. 9. Saltiki K, Doukas C, Kanakakis J, Anastasiou E, Mantzou E, Alevizaki M: Severity of cardiovascular disease in girls: relation with exposure to endogenous estrogen. Maturitas 2006, 55:51?7. ten. Carr MC: The emergence with the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003, 88:2404?411. 11. Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk aspect for cardiovascular disease: a 26 year comply with up of participants inside the Framingham Heart Study. Circulation 1983, 67:968?77. 12.
